CLINICAL_TRIALS trial_result · 2025-11-19

Clinical Trial Update: Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma [Phase 2]

Phase 2 study of magrolimab in combination therapy for head and neck squamous cell carcinoma was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Gilead Sciences | Conditions: Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2025-11-19